Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab

被引：0
|
作者：
Saburi, Masuho
Sakata, Masanori
Kodama, Yousuke
Uraisami, Keiichi
Takata, Hiroyuki
Miyazaki, Yasuhiko
Wada, Junpei
Urabe, Shogo
Ohtsuka, Eiichi
机构：
来源：
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2023年 / 63卷 / 03期
关键词：
diffuse large B-cell lymphoma; polatuzumab vedotin; bendamustine; MYC translocation;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：201 / 204
页数：4
相关论文
共 50 条
  • [1] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, : 201 - 204
  • [2] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [3] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [4] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
    Vodicka, Prokop
    Benesova, Katerina
    Janikova, Andrea
    Prochazka, Vit
    Belada, David
    Mocikova, Heidi
    Steinerova, Katerina
    Duras, Juraj
    Karban, Josef
    Hanackova, Veronika
    Sykorova, Alice
    Obr, Ales
    Trneny, Marek
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
  • [5] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Dal, Mehmet Sinan
    Ulu, Bahar Uncu
    Uzay, Ant
    Akay, Olga Meltem
    Besisik, Sevgi
    Yenerel, Mustafa Nuri
    Celik, Serhat
    Kaynar, Leylagul
    Yucel, Orhan Kemal
    Deveci, Burak
    Sonmez, Mehmet
    Mehtap, Ozgur
    Bekoz, Huseyin Saffet
    Sunu, Cenk
    Salim, Ozan
    Ulas, Turgay
    Karti, Sami
    Altuntas, Fevzi
    Ferhanoglu, Burhan
    Tuglular, Tulin Firat
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 133 - 140
  • [6] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Mehmet Sinan Dal
    Bahar Uncu Ulu
    Ant Uzay
    Olga Meltem Akay
    Sevgi Beşışık
    Mustafa Nuri Yenerel
    Serhat Çelik
    Leylagül Kaynar
    Orhan Kemal Yücel
    Burak Deveci
    Mehmet Sönmez
    Özgür Mehtap
    Hüseyin Saffet Beköz
    Cenk Sunu
    Ozan Salim
    Turgay Ulaş
    Sami Kartı
    Fevzi Altuntaş
    Burhan Ferhanoğlu
    Tülin Fırat Tuğlular
    Annals of Hematology, 2023, 102 : 133 - 140
  • [7] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [8] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [9] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
    Song, Yuqin
    Zhang, Qingyuan
    Cai, Qingqing
    Song, Yongping
    Zhang, Liling
    He, Pengcheng
    Wang, Li
    Hirata, Jamie
    Musick, Lisa
    Deng, Rong
    Liu, Wenxin
    Wang, Xin
    Zhu, Jun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (07) : 2133 - 2140
  • [10] US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
    Betts, Keith A.
    Thuresson, Per-Olof
    Felizzi, Federico
    Du, Ella X.
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Masaquel, Anthony S.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (14) : 1003 - 1015
12345